Pulmatrix (PULM) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings or view top-rated stocks.

1 analysts have issued 1-year price objectives for Pulmatrix's shares. Their PULM share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 360.8% from the stock's current price.
View analysts price targets for PULM or view top-rated stocks among Wall Street analysts.

Pulmatrix's stock was trading at $3.88 at the beginning of 2023. Since then, PULM shares have decreased by 44.1% and is now trading at $2.17.
View the best growth stocks for 2023 here.

Pulmatrix saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,700 shares, a drop of 20.6% from the August 15th total of 3,400 shares. Based on an average trading volume of 12,900 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's shares are sold short.
View Pulmatrix's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PULM earnings forecast.

Pulmatrix, Inc. (NASDAQ:PULM) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.23) by $0.19. The biotechnology company earned $1.84 million during the quarter, compared to the consensus estimate of $1.51 million. Pulmatrix had a negative trailing twelve-month return on equity of 60.14% and a negative net margin of 253.24%.

Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PULM stock can currently be purchased for approximately $2.17.

Pulmatrix (NASDAQ:PULM) has a market capitalization of $7.92 million and generates $6.07 million in revenue each year. The biotechnology company earns $-18,840,000.00 in net income (profit) each year or ($4.85) on an earnings per share basis.

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906.